Published in Pharma Investments, Ventures and Law Weekly, December 26th, 2004
Total operating expenses for the 3 months ended September 30, 2004, totaled $2.6 million, as compared to $2.8 million for the same period in 2003. Research and development expenses increased 32% to $879,000.
Total revenues for the quarter decreased to $613,000 from $1,040,000 in the same quarter in 2003. In the 2003 quarter, we experienced an increase in revenue as a major customer was preparing for the launch of our Medi-Jector VISION device.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly